105 related articles for article (PubMed ID: 22812555)
1. Cost-effectiveness of TNF-α inhibition in active ankylosing spondylitis: a systematic appraisal of the literature.
Kirchhoff TD; Mittendorf T; Schmidt RE; Jablonka A; Merkesdal S
Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):307-17. PubMed ID: 22812555
[TBL] [Abstract][Full Text] [Related]
2. A discrete event modelling framework for simulation of long-term outcomes of sequential treatment strategies for ankylosing spondylitis.
Tran-Duy A; Boonen A; van de Laar MA; Franke AC; Severens JL
Ann Rheum Dis; 2011 Dec; 70(12):2111-8. PubMed ID: 21857027
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada.
Kobelt G; Andlin-Sobocki P; Maksymowych WP
J Rheumatol; 2006 Apr; 33(4):732-40. PubMed ID: 16583476
[TBL] [Abstract][Full Text] [Related]
4. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology.
Keat A; Barkham N; Bhalla A; Gaffney K; Marzo-Ortega H; Paul S; Rogers F; Somerville M; Sturrock R; Wordsworth P;
Rheumatology (Oxford); 2005 Jul; 44(7):939-47. PubMed ID: 15901904
[No Abstract] [Full Text] [Related]
5. Cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in Germany.
Neilson AR; Sieper J; Deeg M
Rheumatology (Oxford); 2010 Nov; 49(11):2122-34. PubMed ID: 20660498
[TBL] [Abstract][Full Text] [Related]
6. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).
Kobelt G; Andlin-Sobocki P; Brophy S; Jönsson L; Calin A; Braun J
Rheumatology (Oxford); 2004 Sep; 43(9):1158-66. PubMed ID: 15226514
[TBL] [Abstract][Full Text] [Related]
7. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.
Barkham N; Kong KO; Tennant A; Fraser A; Hensor E; Keenan AM; Emery P
Rheumatology (Oxford); 2005 Oct; 44(10):1277-81. PubMed ID: 16105913
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice data.
Kobelt G; Sobocki P; Mulero J; Gratacos J; Collantes-Estevez E; Braun J
Scand J Rheumatol; 2008; 37(1):62-71. PubMed ID: 18189197
[TBL] [Abstract][Full Text] [Related]
9. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States.
Schabert VF; Watson C; Gandra SR; Goodman S; Fox KM; Harrison DJ
J Med Econ; 2012; 15(2):264-75. PubMed ID: 22115327
[TBL] [Abstract][Full Text] [Related]
10. Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis.
Boonen A; van den Heuvel R; van Tubergen A; Goossens M; Severens JL; van der Heijde D; van der Linden S
Ann Rheum Dis; 2005 Mar; 64(3):396-402. PubMed ID: 15271773
[TBL] [Abstract][Full Text] [Related]
11. Understanding the role of tumor necrosis factor inhibition in ankylosing spondylitis.
Davis JC
Semin Arthritis Rheum; 2005 Feb; 34(4):668-77. PubMed ID: 15692960
[TBL] [Abstract][Full Text] [Related]
12. The value of persistence in treatment with subcutaneous TNF-alpha inhibitors for ankylosing spondylitis.
Svedbom A; Dalén J; Ivergård M; Borse RH; Black CM; Luttropp K; Kachroo S
Eur J Health Econ; 2020 Feb; 21(1):45-54. PubMed ID: 31522361
[TBL] [Abstract][Full Text] [Related]
13. Vitiligo improvement in a patient with ankylosing spondylitis treated with infliximab.
Simón JA; Burgos-Vargas R
Dermatology; 2008; 216(3):234-5. PubMed ID: 18182816
[TBL] [Abstract][Full Text] [Related]
14. A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis.
Boonen A
Nat Clin Pract Rheumatol; 2006 Oct; 2(10):546-53. PubMed ID: 17016480
[TBL] [Abstract][Full Text] [Related]
15. Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives?
Kiltz U; Heldmann F; Baraliakos X; Braun J
Curr Opin Rheumatol; 2012 May; 24(3):252-60. PubMed ID: 22450391
[TBL] [Abstract][Full Text] [Related]
16. Low-dose infliximab treatment for ankylosing spondylitis--clinically- and cost-effective.
Jois RN; Leeder J; Gibb A; Gaffney K; Macgregor A; Somerville M; Scott DG
Rheumatology (Oxford); 2006 Dec; 45(12):1566-9. PubMed ID: 16705043
[TBL] [Abstract][Full Text] [Related]
17. [Current aspects of cost effectiveness of TNF-alpha blocking agents in patients with rheumatoid arthritis].
Merkesdal S; Ruof J
Z Rheumatol; 2002; 61 Suppl 2():II/29-32. PubMed ID: 12491120
[TBL] [Abstract][Full Text] [Related]
18. Cost of illness from the public payers' perspective in patients with ankylosing spondylitis in rheumatological care.
Strömbeck B; Englund M; Bremander A; Jacobsson LT; Kedza L; Kobelt G; Petersson IF
J Rheumatol; 2010 Nov; 37(11):2348-55. PubMed ID: 20716657
[TBL] [Abstract][Full Text] [Related]
19. Baseline predictors of response to TNF-α blocking therapy in ankylosing spondylitis.
Arends S; van der Veer E; Kallenberg CG; Brouwer E; Spoorenberg A
Curr Opin Rheumatol; 2012 May; 24(3):290-8. PubMed ID: 22418743
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: a randomized controlled trial.
Van Tubergen A; Boonen A; Landewé R; Rutten-Van Mölken M; Van Der Heijde D; Hidding A; Van Der Linden S
Arthritis Rheum; 2002 Oct; 47(5):459-67. PubMed ID: 12382292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
